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Social & economic relevance 
Preterm birth is defined by the World Health Organization (WHO) as birth before 37 
weeks of gestation. It can have a tremendous impact on the health and life of the 
infant after birth (1). Globally, around 15 million infants are born preterm, which is 
more than 1 out of 10 births (1). In The Netherlands, in 2015 7.1% of all births were 
preterm (2). In absolute numbers, this accounted for 12,070 children out of a total 
number of 169,267 infants (2). Although within The Netherlands these numbers show 
a decrease compared to the year of 2013, globally still almost 1 million children die 
every year due to preterm birth-related complications (1, 3). Prematurity remains the 
main cause of death in children younger than five years (1). Even when preterm 
infants survive, they often will face a lifetime with disabilities and health problems (1). 
Therefore, the social and economic impact of preterm birth-related complications on 
families, society and the health care system remains high (2, 4, 5). The psychosocial 
and emotional impact on the family, such as psychological distress and maternal 
depression, mainly depends on the severity of the infant’s health condition (4, 6). The 
economic costs related to preterm birth are large and include acute neonatal 
intensive care, ongoing long-term health care needs and the requirement for special 
education services (4). In The Netherlands, on average, the total number of days spent 
in the neonatal intensive care unit (NICU) and the hospital varied between 11 days 
(for a child born between 34.0-36.6 weeks) and 62 days (for a child born between 
24.0-25.6 weeks) per child within the year of 2015 (2). This indicates the inverse 
relation between the gestational age at birth and the intensity of required neonatal 
care (7). In addition, prematurely born children have a higher chance to be re-
hospitalized (6, 8). Preterm birth-related costs added up to $26.2 billion in the United 
States in 2005; and the first-year medical costs for preterm infants ($32,325) were on 
average roughly ten times higher than the costs for term infants ($3,325) (4). Overall, 
these numbers indicate that preterm birth can be considered as a serious global 
health problem (1, 4). 
Respiratory problems belong to the most common complications in preterm infants 
(9). The development of the lungs into healthy and functional organs is crucial for life 
after birth. As preterm infants are born before completion of the in utero stages of 
lung development, these infants have a higher risk to develop respiratory 
complications either directly after birth or at a later age (such as respiratory distress 
syndrome and wheezing disorders) (9-11). This is especially true when the preterm 
infant is additionally exposed to antenatal inflammation, like chorioamnionitis (9). 
Chorioamnionitis is an intra-uterine inflammation or infection of the chorion and the 
amnion (fetal membranes), and the placenta (12-14). Intra-uterine inflammation is 
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one of the most essential risk factors of preterm birth, as it is involved in up to 50% of 
the preterm births <28 weeks (12, 15). Prematurely born infants who were exposed to 
chorioamnionitis had an increased risk of asthma compared with gestational age-
matched infants who were not exposed to chorioamnionitis, indicating the association 
between exposure to chorioamnionitis and childhood asthma (16). The highest risk of 
asthma (odds ratio [OR] 4.4; 95% CI: 2.2-8.7) and wheezing (OR 4.0; 95% CI: 2.0-8.0) 
was observed in former preterm infants who were exposed to chorioamnionitis and 
who were born at a lower gestational age (16, 17). In addition, antenatal infection or 
inflammation is associated with a higher risk for chronic lung disease if preterm 
infants are postnatally exposed to extended mechanical ventilation or sepsis (18). 
These findings suggest that the consequences of intra-uterine inflammation are not 
limited to life directly after birth and that they can persist into childhood.  
Factors that have contributed to an increased survival rate of preterm infants are 
administration of antenatal corticosteroids to increase pulmonary maturation and 
advancements within mechanical ventilation techniques (5). To realize such new 
advances and to improve current medical technology and neonatal care, extensive 
research is essential and indispensable. As intra-uterine inflammation is such a critical 
risk factor for respiratory complications, this thesis focused on the effects of exposure 
to intra-uterine inflammation on the fetal lungs. Furthermore, in this thesis, the 
pulmonary effects of several therapies such as antenatal corticosteroids and 
interleukin-2 (IL-2) were evaluated and discussed within the setting of intra-uterine 
inflammation. 
 
Novelty & future directions  
Within this thesis, novel insights were presented. High-dose IL-2 therapy has already 
been approved by the US Food and Drug Administration as a treatment for metastatic 
melanoma and renal cell carcinoma (19). Nevertheless, as far as we know, we were 
the first to describe the clinical potential of prophylactic IL-2 treatment for the fetal 
lungs (chapter 3) and the gut (20) in an in vivo setting of intra-uterine inflammation. 
However, more research is required to investigate the use of IL-2 within this new 
indication of intra-uterine inflammation. Currently there are no adequate data 
available regarding the use of human recombinant IL-2 (Proleukin® [aldesleukin]) 
during pregnancy. No sufficient animal research was performed yet to assess the 
safety for the developing fetus, the course of gestation and the peri- and postnatal 
development (21, 22). Therefore, additional pre-clinical studies need to be conducted, 
to assess risks and benefits (23). Future pre-clinical studies will also reveal the effects 
of prophylactic IL-2 when chorioamnionitis is followed by a postnatal second hit (such 
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as mechanical ventilation or sepsis); and whether IL-2 can be used as a therapy after 
the induction of intra-uterine inflammation (instead of the prophylactic approach).  
After sufficient and detailed information is known regarding animal fetal toxicity, 
safety and dosing of IL-2, pre-clinical studies can be followed by clinical studies. 
Clinical trials will be designed in compliance with Good Clinical Practice to test the 
fetal and maternal safety, the efficacy, the dosage and potential side-effects of IL-2 in 
humans (23). 
This thesis also provides novel insights about the timing of exposure to intra-uterine 
inflammation. The data within this thesis clearly indicate that the timing of intra-
uterine inflammation is crucial for the fetal pulmonary outcome. In chapter 2 and in 
(24), it was shown that the order of exposure to intra-amniotic inflammation and 
antenatal corticosteroids influenced the pulmonary inflammatory response and the 
Wnt/β-catenin signaling pathway. Furthermore, the fetal pulmonary inflammatory 
response was shown to be time-dependent and gestation-dependent. It is suggested 
that for the fetal pulmonary outcome multiple factors are crucial: the gestational age 
at the onset of exposure to intra-uterine inflammation, the gestational age at preterm 
birth and the duration of the exposure. This further emphasizes the need for the 
development of reliable biomarkers to detect the presence of intra-uterine 
inflammation during pregnancy. 
 
Potential target groups & activities 
Out of a scientific point of view, the data described within this thesis are of interest to 
scientists and researchers who are working in the field of intra-uterine inflammation, 
preterm birth or pediatric pulmonology. In addition to this scientific audience, the 
findings within this thesis will be of value to clinicians who are specialized in neonatal 
and perinatal care or come into contact with intra-uterine inflammation during their 
daily work. The clinical target group therefore consists –without limitation- of: 
neonatologists, neonatal nurses, pediatricians and (pediatric) pulmonologists. 
Although this thesis focused on the fetal outcomes, instead of the maternal effects, 
after exposure to intra-uterine inflammation, the described findings might also be of 
interest for clinicians who are also involved in maternal medicine, such as 
obstetricians and gynecologists.   
An important non-scientific target group consists of patient associations or parent 
groups. Parent groups are crucial in raising awareness of the health problem and in 
improving the quality of care (4). In Europe, the European Foundation for the Care of 
Newborn Infants (EFCNI) is a network and organization which represents the interests 
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of preterm and ill neonatal infants and their families. It combines the power of all 
stakeholders, such as parents, policy makers, healthcare professionals and scientists 
(25). By doing so, it has successfully increased awareness, political attention and 
policy change regarding preterm birth across Europe (4). In addition, by promoting 
research, the EFCNI gathers and multiplies information to improve the quality of care 
for (ill) neonates (25). As this thesis focuses on the effects of antenatal inflammation 
on fetal lung development, it can be of interest to organizations such as the EFCNI to 
help raise awareness of this specific health problem within our society. Hopefully, 
raising awareness will eventually contribute to the development of new therapeutic 
strategies for this very vulnerable patient group. 
Finally, the data within this thesis can be of interest to the pharmaceutical industry, as 
therapeutic interventions and strategies were discussed within this thesis. While the 
use of corticosteroids within the field of perinatology is not new, we are the first to 
present the potential of prophylactic IL-2 therapy for the lungs in a translational 
setting of intra-uterine inflammation (chapter 3). The pharmaceutical industry could 
be of help and support to further investigate the potential of IL-2 within the context of 
antenatal inflammation. 
To reach these target groups and to make individuals within and outside of the 
scientific community aware or our findings, we published our research data in peer-
reviewed scientific journals relevant to our field of research, such as Pediatric 
Research (chapter 2) and the American Journal of Physiology Lung Cellular and 
Molecular Physiology (chapter 3). Furthermore, the findings described within this 
thesis were presented to (inter)national audiences via oral and poster presentations 
at a conference, symposium, science day or research meeting.  
To summarize, the data reported within this thesis are scientifically, socially and 
economically relevant. Therefore, the content of this thesis can be of interest to 
target groups within and outside of the scientific and clinical community. Although the 
results described within this thesis were obtained using a translational pre-clinical 
model, these data contribute to our knowledge regarding intra-uterine inflammation 
and its pulmonary effects; and may eventually lead to the set-up of novel clinical 
studies and the discovery of new medical advancements. Only innovations within the 
field of gynecology, neonatology and perinatology will in time lead to a reduction in 
the occurrence and severity of intra-uterine inflammation and the pulmonary 
complications associated with this indication. Reducing the prevalence and severity 
will also lower health care costs and the burden on the infant and its family, ultimately 
leading to a reduction in the economic and social impact of intra-uterine inflammation 
and its associated pulmonary effects.     
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